MEDTECH NEWS

This article outlines the clinical trial design for assessing the safety and effectiveness of a single-port laparoscopic surgical system in gynecological surgeries. The trial adopts a prospective, single-group design, targeting common high-risk gynecological procedures. Key evaluation metrics include the non-conversion rate and complications graded Clavien-Dindo 3 or higher within 30 days post-operation, alongside secondary endpoints like surgery duration, intraoperative blood loss, patient pain scores, and overall complication rates. With a sample size of 60 cases, determined from expected performance data and dropout rates, the trial covers representative procedures such as radical hysterectomy and comprehensive staging surgery for endometrial cancer. Statistical analysis follows established guidelines to ensure rigorous assessment of the system's efficacy and safety.

In April 2024, China's National Medical Products Administration (NMPA) approved 292 medical device products, including various innovative devices such as single-use surgical instruments, advanced diagnostic kits, and therapeutic devices from notable companies like Volcano AtheroMed Inc., Integra LifeSciences, and Abbott Medical. These approvals span across domestic and imported devices, highlighting the NMPA's focus on expanding access to advanced medical technologies.

The National Medical Products Administration (NMPA) issued a clarification on March 27, 2024, regarding the classification of Radiofrequency (RF) Therapy Devices, categorizing certain RF devices for skin treatment as Class III medical devices. This directive, part of the adjustments under Announcement No. 30 (2022), aims to ensure rigorous regulatory oversight for RF devices used in therapeutic skin treatments, emphasizing safety and efficacy. The move by the NMPA sets a clear regulatory path for the development and use of RF therapy devices, aligning with patient safety and product innovation standards.

On March 19, 2024, the National Medical Products Administration's (NMPA) Center for Medical Device Evaluation in China released the "Guidelines for Usability Engineering in Medical Device Registration," aiming to standardize usability engineering practices for medical devices to ensure their safety and effectiveness through improved user interface design.

China's NMPA CMDE has introduced five new registration review guidelines for specific medical devices, including Monkeypox Virus Nucleic Acid Test Kits, Corneal Topography Devices, Laparoscopic Surgical Systems, and Medical Device Optical Radiation Safety, bringing the total number of effective guidelines to 613 by the end of 2023, covering 92.2% of China's medical device classification catalog.

The approval of 193 medical devices by NMPA in February 2024, including advanced Class III and Class II equipment, marks a significant advancement in healthcare technology, catering to diverse medical needs and enhancing patient care.

The NMPA's approval of Hangzhou Tangji Medical Technology's innovative Gastric Bypass Stent System introduces a non-surgical obesity management solution, promising a safer alternative for effective weight loss.

The "Guidance on Real-World Study Design and Statistical Analysis for Medical Device Registration Review" issued by the NMPA and CMDE on January 10, 2024, revolutionizes the use of real-world data in China's medical device clinical evaluations, enhancing device safety and efficacy assessments in real-life applications.